What question did this study set out to answer?

To describe the therapeutic feasibility of lenvatinib as neoadjuvant chemotherapy to enable interval debulking surgery in initially unresectable papillary thyroid carcinoma with vascular invasion.

January 1, 2020Case Reports in EndocrinologyOpen Access

A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy

View Full Paper

Ask AI

Bookmark

Authors

HIHiroyuki IwasakiKanagawa Prefectural Hospital Organization STSoji TodaKanagawa Prefectural Hospital Organization HIHiroyuki ItoKanagawa Prefectural Hospital Organization

Discussion

Member takes

Implication

Case report demonstrates tumor shrinkage and successful resection following neoadjuvant lenvatinib in unresectable papillary thyroid carcinoma, suggesting a viable downstaging strategy.

Key Points

To describe the therapeutic feasibility of lenvatinib as neoadjuvant chemotherapy to enable interval debulking surgery in initially unresectable papillary thyroid carcinoma with vascular invasion.
Administered lenvatinib over 4 months as off-label neoadjuvant therapy under institutional review board approval in a 75-year-old female with unresectable papillary thyroid carcinoma and extensive venous invasion.
Assessed tumor size reduction and metastatic status via computed tomography before performing interval debulking surgery and subsequent clinical follow-up.
Lenvatinib treatment induced significant tumor shrinkage over 4 months, converting the extensive neck and mediastinal mass into a surgically resectable lesion.
At 3 months post-surgery, the patient remained alive with complete resolution of lung metastases on follow-up computed tomography imaging.

Cite This Study

Iwasaki et al. (2020) studied this question.

synapsesocial.com/papers/6a82563347f72330e2ffbc92 https://doi.org/10.1155/2020/6438352

View Full Paper

Ask AI

Bookmark

Implication

Case report demonstrates tumor shrinkage and successful resection following neoadjuvant lenvatinib in unresectable papillary thyroid carcinoma, suggesting a viable downstaging strategy.

A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider